Hims & Hers Health, a direct-to-consumer virtual care company, reported a remarkable 52% year-over-year revenue increase, from $207.9 million in Q2 2023 to $315.6 million in Q2 2024. The San Francisco-based company achieved a net income of $13.3 million, a significant turnaround from a net loss of $7.2 million the previous year. Adjusted EBITDA surged to $39.3 million from $10.6 million, while free cash flow grew to $47.6 million from $10 million. The company raised its full-year 2024 revenue guidance to between $1.37 billion and $1.4 billion, with adjusted EBITDA projected between $140 million and $155 million. CEO Andrew Dudum highlighted the 43% increase in platform subscribers, reaching 1.9 million, and expressed confidence in expanding platform capabilities to benefit more individuals.
Teletherapy company Talkspace announced a 29% year-over-year revenue increase, reaching $46.1 million in Q2 2024. This growth was driven by a 62% increase in payor revenue and a 20% rise in revenue from its Direct-to-Enterprise sector, despite a 28% decline in consumer revenue. Operating expenses increased slightly by 1% to $24.4 million, leading to an 18% rise in gross profit to $21 million. The net loss improved to $0.5 million from $4.7 million, primarily due to increased revenue. Adjusted EBITDA improved to $1.2 million, compared to a loss of $4 million in Q2 2023. CEO Dr. Jon Cohen highlighted the company's commitment to enhancing provider and patient experiences, contributing to the positive momentum and making high-quality mental health care more accessible.
Clover Health, a Medicare Advantage insurtech company based in Tennessee, reported 11% year-over-year revenue growth to $356.3 million in Q2 2024, up from $320.1 million in Q2 2023. The company achieved its first positive GAAP net income as a public company, reporting $7.2 million compared to a loss of $28.9 million in the same quarter last year. Adjusted EBITDA also increased significantly to $36.2 million from $9.9 million. Clover Health raised its full-year revenue guidance to between $1.35 billion and $1.375 billion, with adjusted EBITDA guidance now ranging from $50 million to $65 million. CFO Peter Kuipers attributed the strong performance to the company's robust balance sheet and improved full-year guidance, alongside a recent increase in the company's Star Rating for the 2025 payment year, positioning Clover Health well for long-term profitability.
Click here to read the original news story.